<DOC>
	<DOCNO>NCT01413763</DOCNO>
	<brief_summary>The purpose study determine potential effect topically apply 3.75 % imiquimod cream atrial ectopy actinic keratosis ( AK ) patient . The primary endpoint change 24-hour supraventricular premature beat count . The secondary endpoint change 24-hour supraventricular premature couplet run count atrial fibrillation ( % time ) ; change 24-hour mean heart rate ; change 24-hour ventricular premature beat count , ventricular premature couplet run count .</brief_summary>
	<brief_title>Potential Effect Topical Imiquimod Atrial Ectopy Patients With Actinic Keratosis</brief_title>
	<detailed_description>This study double-blind , randomize , placebo-controlled , 2-way crossover study design ass potential effect topically apply 3.75 % imiquimod cream atrial ectopy actinic keratosis ( AK ) patient . Candidates study participation begin screen procedure 28 day prior enrollment . Qualified subject shall admit CRU Day -1 baseline evaluation randomize one two possible treatment sequence . Each subject receive active 3.75 % imiquimod cream match placebo randomize crossover fashion 2-week washout treatment . The application area entire face ( exclusive naris , vermilion , periocular area ear ) bald scalp . Atrial ectopy monitor 24 hour Baseline ( Day -1 ; prior first dose study medication ) , conclusion 14-day treatment period use continuous 12-lead digital Holter recorder . Adverse event , concomitant medication use , study medication accountability , subject compliance review visit .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>Male female AK patient least 5 typical visible palpable AK lesion face bald scalp AK patient otherwise good general health age 18 year Female subject childbearing potential must nonpregnant nonlactating Previous clinical study participation within 30 day ( drug device ) Evidence clinically significant disease History drug alcohol abuse Subjects uncontrolled systemic hypertension , NYHA heart failure classification Class &gt; II , history atrial fibrillation atrial flutter Subjects use imiquimod interferon within 30 day prior first dose study medication Have know allergy excipient study cream Have melanoma anywhere body</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Actinic keratosis</keyword>
	<keyword>Atrial ectopy</keyword>
</DOC>